Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Indofarma Tbk. (INAF) vs Niramas Utama Tbk. (JELI) Price & Performance

Indofarma Tbk.Trade
Niramas Utama Tbk.Trade

Price performance (Past 24H)

Key statistics

Indofarma Tbk. vs Niramas Utama Tbk. — how do they compare? Indofarma Tbk. trades at Rp126 (market cap 390.51B), while Niramas Utama Tbk. trades at Rp515 (market cap 670.98B, 3.31M 24h volume). The key difference: Niramas Utama Tbk. is the larger of the two by market cap. Which is the better fit depends on your goals.

INAFJELI
Market Cap
390.51B670.98B
Volume
3.31M
Lot
33.07K
Turnover
1.71B
Average Price
516.6
Value
1.71B
Indicative Equilibrium Price
515
Indicative Equilibrium Volume
680

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

INAF
View details
JELI
View details

About Indofarma Tbk.

PT Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk (the Company) was established based on Deed No. 1 dated January 2, 1996 as amended by Deed No. 134 dated January 26, 1996 both of Notary Sutjipto, SH. PT. Indofarma, Tbk began as medicine factory well known as "Pabrik Obat Manggarai". Then take over by Japan's Government from Nederland's Government on 1942. On 1950 the Indonesian Government acquisited the factory by Department of Health and functioned as center of pharmacy production for its department. On 1979 the name changed to be Department of Health Center of Pharmacy Production as non Profit institution as main assignment to produced medicine for public service. Then the Company changed the name as PT. Indonesia Farma Tbk, known as PT Indofarma (Persero) Tbk.

Read more on INAF

About Niramas Utama Tbk.

PT. Niramas Utama Tbk. (the Company) formerly PT Nata Sari Raya was established based on Notarial Deed No. 86 dated 22 November 1990, by Notary Samsul Hadi, S.H. The Company started its commercial operations in 1994. The parent entity and the ultimate parent entity of the Company are PT Niramas Utama International and PT Supra Sentral Investama

Read more on JELI